Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $35.1252W HIGH $64.16
Volume
11.71 M
Value Traded
484.19 M
Short % Float
1.14%
Days to Cover
4.0
+0.6%Week
+6.14%1 Month
-7.24%3 Month
-5.98%6 Month
+10.33%5 Year
+28,000%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
185.88 B
EPS (TTM)
4.27
P/E Ratio
9.76
Ent. Value
218.18 B
Total Shares
4.46 B
Float Shares
3.35 B
Insiders
0.01%
Institutions
9.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
NVO Catalyst Timeline
Dated clinical, regulatory and corporate events for Novo Nordisk A/S
Catalyst Timeline
Dated clinical, regulatory & corporate events for Novo Nordisk A/S
102Total events
13Upcoming
43Tier-1 (high impact)
2025 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲EU ApprovalDenecimigFiledEx-US Regulatory
European Commission grants marketing authorisation for FREHEMGO (denecimig) in haemophilia A
haemophilia A (congenital FVIII deficiency), with or without inhibitorssource ↗
▲Grant / FundingCorporate
Novo Nordisk commits USD 200 million to World Diabetes Foundation for 2027-2036
▼Timing GuidanceDenecimigFiledPresentation
FDA informed Novo denecimig BLA review is still ongoing with no new timeline for regulatory action
haemophilia Asource ↗
▼Approval Delay AnnouncedDenecimigFiledFDA Decision
FDA informed Novo that denecimig BLA review is extended due to ongoing facility remediation activities
haemophilia Asource ↗
●Quarterly UpdateCorporate
Weekly share repurchase transactions reported (28 September – 2 October 2026)
▲Additional DataSemaglutideApprovedClinical Data
Post hoc analysis of STEP UP sub-population shows semaglutide reduced liver fat to normal levels in 9 of 10 adults
Obesity with excess liver fatsource ↗
▲Oral PresentationSemaglutideApprovedPresentation
STEP UP pooled liver analysis presented at EASD Annual Meeting 2026
Obesity with excess liver fatsource ↗
▲Topline ReadoutCagriSemaFiledClinical Data
REIMAGINE 1 MRI sub-study data presented at EASD 2026 showing reductions in abdominal, liver and pancreas fat with 14.3% weight reduction at week 40
Early type 2 diabetessource ↗
●Quarterly UpdateCorporate
Cumulative repurchases since 4 February 2026 total 35,379,179 B shares
▲Partnership / LicenseCorporate
Orbis Medicines enters multi-target drug discovery partnership with Novo Nordisk worth up to USD 1.4 billion
cardiometabolic diseasessource ↗
▲CHMP Positive OpinionDenecimigFiledEx-US Regulatory
Denecimig received a positive CHMP opinion
haemophilia Asource ↗
▲CHMP Positive OpinionDenecimigFiledEx-US Regulatory
Frehemgo (denecimig) received positive CHMP opinion
▲Primary Endpoint MetSemaglutideApprovedClinical Data
STEP Young phase 3 met primary endpoint of BMI reduction at week 68
obesity in children aged 6 to under 12 yearssource ↗
▲Topline ReadoutSemaglutideApprovedClinical Data
First results from STEP Young phase 3 trial announced
obesity in children aged 6 to under 12 yearssource ↗
▲CHMP Positive OpinionDenecimigFiledEx-US Regulatory
CHMP adopts positive opinion for FREHEMGO (denecimig) in haemophilia A
haemophilia A (congenital FVIII deficiency), with or without inhibitorssource ↗
▲Partnership / LicenseCorporate
Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI
▲IP Litigation RulingSemaglutideApprovedIP / Competition
Dutch court grants preliminary injunction against Ceban for infringing semaglutide SPC
▲Partnership / LicenseCorporate
H1 partners with Novo Nordisk to scale AI-driven clinical development
▼Primary Endpoint MissedZiltivekimabClinical Data
ZEUS phase 3 trial with ziltivekimab did not meet primary endpoint
cardiovascular diseasesource ↗
▼Quarterly UpdateMonlunabantDiscontinuedCorporate
Non-cash impairment charge of DKK 4.0 billion related to monlunabant
▼Program DiscontinuationMonlunabantDiscontinuedCorporate
Impairment charge related to monlunabant
▼Topline ReadoutZiltivekimabClinical Data
ZEUS topline results announced: MACE risk reduction not met
atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammationsource ↗
▼Primary Endpoint MissedZiltivekimabClinical Data
ZEUS primary endpoint missed: no MACE benefit
atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammationsource ↗
◆IP Litigation RulingIP / Competition
Novo Nordisk files lawsuit against Eli Lilly for false advertising of Zepbound and Mounjaro
▲Full ResultsWegovyApprovedClinical Data
STEP UP trial results for Wegovy 7.2 mg showing ~19% weight loss
obesitysource ↗
▲Product LaunchKyinsu®Post-Market
Launch of Kyinsu® on Fangzhou's Internet hospital platform in China
type 2 diabetessource ↗
▲EU ApprovalWegovy®pillApprovedEx-US Regulatory
EC approval of Wegovy pill for weight management
obesity and overweightsource ↗
▲Oral PresentationDenecimigFiledPresentation
Interim FRONTIER4 data presented at ISTH 2026
hemophilia Asource ↗
▲Poster PresentationDenecimigFiledPresentation
Patient-reported outcomes from FRONTIER4 presented at ISTH 2026
hemophilia Asource ↗
▲Oral PresentationConcizumabApprovedPresentation
First-time explorer10 data presented at ISTH 2026
hemophilia A or B with inhibitorssource ↗
▲Product LaunchWegovy®pillApprovedPost-Market
Launch of Wegovy pill in more countries in 2H 2026
obesity and overweightsource ↗
◆Timing GuidanceDenecimigFiledPresentation
Anticipated FDA regulatory decision for denecimig BLA in Q3 2026
haemophilia Asource ↗
▲Topline ReadoutCagriSemaFiledClinical Data
CagriSema (1.0/1.0 mg) achieved superior weight loss vs tirzepatide with non-inferior HbA1c reduction in REIMAGINE 5
type 2 diabetes and obesitysource ↗
▲MHRA MilestoneWegovy®pillApprovedEx-US Regulatory
MHRA approval of Wegovy®pill (semaglutide tablets) for weight management in the UK
obesity or overweight with weight-related conditionsource ↗
▲Full ResultsSemaglutideApprovedClinical Data
OASIS 4 topline results: semaglutide tablets 25 mg achieved ~14% weight loss vs ~2% placebo (treatment policy) and ~17% vs ~3% (on-treatment) at 64 weeks
obesity or overweight with weight-related condition without diabetessource ↗
Past FDA Catalysts and PDUFA Decisions
How NVO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-23 | Awiqli Flextouch (insulin icodec) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
65
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma(rank 8 of 689)
Percentile Rank
Commercial products (revenue basis: latest annual revenue in its 20-F, converted from DKK to USD, to Dec 2025; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Ozempic | |||
| Wegovy | |||
| Rybelsus | |||
| NovoRapid And NovoLog | |||
| Tresiba | |||
| NovoSeven | |||
| Ryzodeg | |||
| NovoMix And NovoLog Mix | |||
| Xultophy | |||
| Saxenda | |||
| Victoza | |||
| Fiasp |
Top 12 of 17 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NNC0487-0111 Small MoleculesNCT07533175 | Diabetes Mellitus | Phase 3 | ACTIVE NOT_RECRUITING | 718 | Aug 7, 2028 | ||||||
| NNC0487-0111 Small MoleculesNCT07400107 | Obesity | Phase 3 | ACTIVE NOT_RECRUITING | 10,165 | Dec 19, 2028 | ||||||
| Cagrilintide PeptidesNCT05567796 | Obesity | Phase 3 | ACTIVE NOT_RECRUITING | 6,004 | Oct 19, 2026 | ||||||
| Cagrilintide PeptidesNCT07220759 | Overweight | Phase 3 | ACTIVE NOT_RECRUITING | 2,609 | Jun 30, 2027 | ||||||
| Insulin icodec Small MoleculesNCT07076199 | Diabetes Mellitus, Type 1 | Phase 3 | ACTIVE NOT_RECRUITING | 1,549 | Mar 1, 2027 | ||||||
| Cagrilintide PeptidesNCT05669755 | Cardiovascular Disease | Phase 3 | ACTIVE NOT_RECRUITING | 7,101 | Oct 14, 2027 | ||||||
| CagriSema PeptidesNCT07184086 | Obesity | Phase 3 | ACTIVE NOT_RECRUITING | 3,207 | Feb 9, 2028 | ||||||
| CagriSema PeptidesNCT07919405 | Hypertension | Phase 3 | NOT YET_RECRUITING | 1,408 | Jul 13, 2028 | ||||||
| Zenagamtide PeptidesNCT07668401 | Obesity | Phase 3 | NOT YET_RECRUITING | 400 | Jan 11, 2029 | ||||||
| Zenagamtide PeptidesNCT07815067 | Overweight | Phase 3 | RECRUITING | 1,980 | Jun 12, 2028 | ||||||
| Zenagamtide PeptidesNCT07797335 | Type 2 Diabetes | Phase 3 | RECRUITING | 1,778 | Sep 20, 2028 | ||||||
| Zenagamtide PeptidesNCT07861100 | Cardiovascular Risk | Phase 3 | NOT YET_RECRUITING | 8,500 | Sep 16, 2030 | ||||||
| UBT251 Small MoleculesNCT07710729 | Overweight | Phase 2 | RECRUITING | 373 | Apr 27, 2027 | ||||||
| UBT251 Small MoleculesNCT07668388 | Diabetes Mellitus, Type 2 | Phase 2 | RECRUITING | 300 | Nov 15, 2027 | ||||||
| NNC0662-0419 Small MoleculesNCT07525791 | Overweight | Phase 2 | ACTIVE NOT_RECRUITING | 465 | Jun 18, 2027 | ||||||
| NNC0662-0419 Small MoleculesNCT07639021 | Obesity | Phase 2 | ACTIVE NOT_RECRUITING | 233 | Jun 14, 2027 | ||||||
| NNC0662-0419 Small MoleculesNCT07415954 | Diabetes Mellitus, Type 2 | Phase 2 | RECRUITING | 270 | Oct 1, 2027 | ||||||
| NNC0519-0130 Small MoleculesNCT06717698 | Chronic Kidney Disease | Phase 2 | RECRUITING | 465 | Sep 17, 2026 | ||||||
| UBT251 Small MoleculesNCT07710768 | Obesity | Phase 1 | RECRUITING | 44 | Apr 7, 2027 | ||||||
| Ziltivekimab BiologicsNCT06200207 | Heart Failure | Phase 3 | ACTIVE NOT_RECRUITING | 673 | Jan 8, 2027 | ||||||
| Ziltivekimab BiologicsNCT06118281 | Cardiovascular Risk | Phase 3 | ACTIVE NOT_RECRUITING | 10,000 | Jan 29, 2027 | ||||||
| Ziltivekimab BiologicsNCT07301034 | Myocardial Infarction | Phase 3 | RECRUITING | 332 | Feb 24, 2029 | ||||||
| Ziltivekimab BiologicsNCT07276282 | Coronary Artery Disease | Phase 3 | RECRUITING | 332 | Dec 1, 2028 | ||||||
| NNC9836-0001 Small MoleculesNCT07896109 | Diabetes Mellitus, Type 2 | Phase 1 | RECRUITING | 121 | Jul 26, 2028 | ||||||
| NNC1679-0001 Small MoleculesNCT07570992 | Diabetes Mellitus, Type 2 | Phase 1 | RECRUITING | 58 | Jun 25, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every NVO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CagriSema | obesity and type 2 diabetes | Phase 3a | 2026-09-30 | 22.4% reduction in body weight versus placebo at 52 weeks; 14.3% body-weight reduction at week 40; 14.2% body-weight reduction with CagriSema at week 68Read More | Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health · EASD 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in NVO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.1 % | 28.76 M | 600.00 K |
Ownership Trends
NVO Short Interest
Shares sold short, counted twice a month.
1.14%
Short % of Float
of tradable shares sold short
38.3M
Shares Sold Short
+2.3% vs prior count
4.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
9.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NVO ranks across every disease it competes in
Competitive Position is a premium feature
See how NVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNVO News
NVO▲ +2.4%today
FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
The European Commission has approved FREHEMGO® (denecimig) for haemophilia A, allowing flexible dosing options for patients. This treatment is the first of its kind to offer once-monthly, every-two-weeks, or weekly administration. The approval follows positive results from the FRONTIER clinical trials, demonstrating significant reductions in bleeding rates. Novo plans to launch the product in Europe in the coming year.
Read more →NVO▲ +2.4%today
Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care
Novo Nordisk announced a USD 200 million commitment to the World Diabetes Foundation for 2027-2036. This funding aims to enhance diabetes prevention and care in low- and middle-income countries. The long-term support will enable WDF to strengthen local health systems and improve access for underserved communities. The initiative reflects a commitment to addressing the growing global diabetes crisis.
Read more →NVONovo Nordisk A/S - share repurchase programme
Novo Nordisk launched a share repurchase programme on May 6, 2026, with a budget of up to DKK 15 billion. As of November 6, 2026, the company has repurchased 42,604,179 B shares at an average price of DKK 277.16. The programme aims to enhance shareholder value over a 12-month period.
Read more →NVONovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk disclosed share trading activities by its board members and executives, in compliance with market regulations. The company emphasizes its commitment to health and sustainability, supported by a global workforce of over 66,500. This announcement reflects transparency in corporate governance.
Read more →NVONovo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million
Novo Nordisk reported a 27% increase in Q3 adjusted operating profit, driven by GLP-1 sales growth. The company launched the Wegovy® pill in several countries, enhancing its market presence. Despite a 9% decrease in reported operating profit due to impairment charges, Novo raised its full-year outlook for sales and profit, reflecting strong performance in its obesity portfolio.
Read more →NVONovo Nordisk A/S – Share repurchase programme
Novo Nordisk has initiated a share repurchase program on May 6, 2026, as part of a larger initiative to buy back shares worth up to DKK 15 billion over 12 months. As of October 2, 2026, the company has repurchased 36,604,179 B shares, totaling approximately DKK 10.25 billion. This move is aimed at enhancing shareholder value and reflects the company's strong market position.
Read more →NVONovo provides update on the denecimig Biologics License Application (BLA) in the US
Novo Nordisk announced that the FDA's review of the Biologics License Application for denecimig, a treatment for haemophilia A, is ongoing. The FDA has not identified any deficiencies in the clinical data but has extended the review due to facility remediation activities. Novo aims to launch denecimig in the US in the first half of 2027, despite the delays.
Read more →NVONovo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026
Novo Nordisk reported that its drug Wegovy® (semaglutide) significantly reduced liver fat in adults with obesity. In a sub-population analysis from the STEP UP trial, 88.5% of participants with elevated liver fat achieved normal levels after 72 weeks of treatment. The average liver fat percentage decreased from 8.8% to 3.1%, indicating improved liver health.
Read more →NVONovo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
Novo Nordisk presented promising new data on CagriSema at the EASD Annual Meeting 2026. The investigational drug demonstrated significant effects on reducing cravings and improving eating behavior in individuals with obesity. Additionally, it showed beneficial impacts on abdominal fat and bone health in adults with type 2 diabetes. These findings suggest CagriSema may address underlying factors of obesity and diabetes beyond weight loss.
Read more →NVONovo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
Novo Nordisk has entered an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist. The deal is valued at up to $2.6 billion, including a $300 million upfront payment. HRS-1596 aims to offer once-weekly oral dosing, potentially enhancing treatment convenience for obesity and type 2 diabetes. The agreement excludes certain regions in Asia and is subject to regulatory approvals.
Read more →NVONovo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial
Novo Nordisk announced positive topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials, demonstrating that CagriSema 1.0 mg/1.0 mg resulted in superior weight loss compared to tirzepatide 5 mg in adults with type 2 diabetes. Additionally, CagriSema showed significant weight reduction versus placebo in overweight or obese participants. The treatment was well tolerated, with a safety profile consistent with previous studies.
Read more →NVONovo and UNICEF expand partnership to support a healthier start for more than 80 million children
Novo Nordisk and UNICEF have announced a four-year expansion of their partnership to combat childhood obesity, targeting over 80 million children in seven countries. The initiative will focus on creating healthier environments and promoting better nutrition and physical activity. Novo is investing $18 million from 2026 to 2030 to support this program, which aims to implement evidence-based policies and interventions.
Read more →NVO▼ -8%on this newsshared move
Highlights to be presented at Novo’s Capital Markets Day 2026
Novo Nordisk is hosting its Capital Markets Day in London, outlining its corporate strategy and ambitions for 2030. Key highlights include plans to launch more than five multi-blockbuster drugs and to serve over 60 million patients globally. The company aims for sustainable growth and attractive returns while maintaining a stable operating margin.
Read more →NVONovo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)
Novo Nordisk's Sogroya® (somapacitan) has received a positive opinion from the CHMP for treating idiopathic short stature (ISS) in children. This would mark the first approved growth hormone therapy for ISS in the EU, addressing a significant unmet need. The recommendation follows previous approvals for other conditions, with a decision from the European Commission expected later this year.
Read more →About Novo Nordisk A/S
BIOPHARMAWATCH ELITE
Trade the next NVO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime